News

Public · Published

Cinven To Buy Women'S Health Group Theramex In €2.6 Billion Deal - FT

Carlyle and PAI have agreed to sell the women's health business Theramex to private equity group Cinven in a deal worth €2.6 billion, according to the FT.

Published:

Updated:

What happened

Carlyle and PAI have agreed to sell the women's health business Theramex to private equity group Cinven in a deal worth €2.6 billion, according to the FT.

Confirmed

Global impact / market context

This sale lets Carlyle and PAI turn their ownership of Theramex into cash, while Cinven takes on the company. For investors, it signals private equity firms are still willing to buy whole healthcare businesses at large prices.

Analyst inference

A €2.6 billion buyout of a women's health company shows dealmaking continues in healthcare, which can support valuations for similar businesses. It also ties up buyer capital in one company, which may limit Cinven's room for other purchases.

Analyst inference

What to watch

  1. Watch whether the €2.6 billion deal closes, since the article only reports the agreement to sell Theramex to Cinven. Confirmed
  2. Watch whether Cinven spends more on Theramex after buying it, such as on research or product launches, which would raise its total cost. Analyst inference
  3. Watch for other women's health companies being sold, because a completed deal can encourage more owners to seek buyers. Analyst inference

Evidence

  • Original source link unavailable